Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005;9(6):R710-7.
doi: 10.1186/cc3883. Epub 2005 Oct 25.

The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis

Kwok M Ho  1 , Jeffrey Lipman, Geoffrey J Dobb, Steven A R Webb
Affiliations
Review

The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis

Kwok M Ho et al. Crit Care. 2005.

Abstract

Introduction: High-risk surgical patients are at increased risk of fungal infections and candidaemia. Evidence from observational and small randomised controlled studies suggests that prophylactic fluconazole may be effective in reducing fungal infection and mortality. We evaluated the effects of prophylactic fluconazole on the incidence of candidaemia and hospital mortality in immunocompetent high-risk surgical patients.

Methods: Randomised controlled studies involving the use of fluconazole in immunocompetent high-risk surgical patients from the Cochrane Controlled Trial Register (2005, issue 1) and from the EMBASE and MEDLINE databases (1966-30 April 2005), without any language restriction, were included. Two reviewers reviewed the quality of the studies and performed data extraction independently.

Results: Seven randomised controlled studies with a total of 814 immunocompetent high-risk surgical patients were considered. The use of prophylactic fluconazole was associated with a reduction in the proportion of patients with candidaemia (relative risk [RR] = 0.21, 95% confidence interval [CI] = 0.06-0.72, P = 0.01; I2 = 0%) and fungal infections other than lower urinary tract infection (RR = 0.39, 95% CI = 0.24-0.65, P = 0.0003; I2 = 0%), but was associated with only a trend towards a reduction in hospital mortality (RR = 0.82, 95% CI = 0.62-1.08, P = 0.15; I2 = 7%). The proportion of patients requiring systemic amphotericin B as a rescue therapy for systemic fungal infection was lower after prophylactic use of fluconazole (RR = 0.35, 95% CI = 0.17-0.72, P = 0.004; I2 = 0%). The proportion of patients colonised with or infected with fluconazole-resistant fungi was not significantly different between the fluconazole group and the placebo group (RR = 0.66, 95% CI = 0.22-1.96, P = 0.46; I2 = 0%).

Conclusion: The use of prophylactic fluconazole in immunocompetent high-risk surgical patients is associated with a reduced incidence of candidaemia but with only a trend towards a reduction in hospital mortality.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart showing study inclusion and exclusion in this meta-analysis.
Figure 2
Figure 2
Forest plot showing the effect of prophylactic fluconazole on hospital mortality. RR, relative risk; CI, confidence interval.
Figure 3
Figure 3
Forest plot showing the effect of prophylactic fluconazole on the proportion of patients with candidaemia. RR, relative risk; CI, confidence interval.
Figure 4
Figure 4
Forest plot showing the effect of prophylactic fluconazole on the proportion of patients with fungal infections. RR, relative risk; CI, confidence interval.
Figure 5
Figure 5
Forest plot showing the effect of fluconazole on proportion of patients colonised with fluconazole-resistant fungi. RR, relative risk; CI, confidence interval.
Figure 6
Figure 6
Funnel plot showing the possibility of a small publication bias. RR, relative risk.
See this image and copyright information in PMC

Comment in

References

    1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317. doi: 10.1086/421946. - DOI - PubMed
    1. Lipman J, Saadia R. Fungal infections in critically ill patients. BMJ. 1997;315:266–267. - PMC - PubMed
    1. Dimopoulos G, Piagnerelli M, Berre J, Eddafali B, Salmon I, Vincent JL. Disseminated aspergillosis in intensive care unit patients: an autopsy study. J Chemother. 2003;15:71–75. doi: 10.1159/000070766. - DOI - PubMed
    1. Tufano R. Focus on risk factors for fungal infections in ICU patients. Minerva Anestesiol. 2002;68:269–272. - PubMed
    1. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis. 2003;3:772–785. doi: 10.1016/S1473-3099(03)00831-4. - DOI - PubMed

MeSH terms